Renal function stratified dose comparisons of eplerenone versus placebo in the EMPHASIS-HF trial.
Aged
Biological Availability
Dose-Response Relationship, Drug
Drug Monitoring
/ methods
Eplerenone
/ administration & dosage
Female
Glomerular Filtration Rate
/ drug effects
Heart Failure
/ diagnosis
Hospitalization
/ statistics & numerical data
Humans
Kidney Function Tests
/ methods
Male
Middle Aged
Mineralocorticoid Receptor Antagonists
/ administration & dosage
Pharmacovigilance
Treatment Outcome
Eplerenone
Heart failure
Renal function
Stratification
Treatment dose
Journal
European journal of heart failure
ISSN: 1879-0844
Titre abrégé: Eur J Heart Fail
Pays: England
ID NLM: 100887595
Informations de publication
Date de publication:
03 2019
03 2019
Historique:
received:
29
08
2018
revised:
02
11
2018
accepted:
22
11
2018
pubmed:
16
2
2019
medline:
18
12
2019
entrez:
16
2
2019
Statut:
ppublish
Résumé
Current heart failure guidelines recommend target eplerenone dose of 50 mg/day. We have examined the effect of different eplerenone doses based on pre-specified renal function stratification in the Eplerenone in Mild Patients Hospitalization and Survival Study in Heart Failure (EMPHASIS-HF). In EMPHASIS-HF, the target dose of eplerenone/placebo was stratified at randomization according to estimated glomerular filtration rate (eGFR): 50 mg/day if eGFR ≥ 50 mL/min/1.73 m In EMPHASIS-HF the eplerenone dose was stratified according to renal function and the treatment effect was not influenced by renal function: 25 mg/day in patients with eGFR 30-49 mL/min/1.73 m
Sections du résumé
BACKGROUND
Current heart failure guidelines recommend target eplerenone dose of 50 mg/day. We have examined the effect of different eplerenone doses based on pre-specified renal function stratification in the Eplerenone in Mild Patients Hospitalization and Survival Study in Heart Failure (EMPHASIS-HF).
METHODS AND RESULTS
In EMPHASIS-HF, the target dose of eplerenone/placebo was stratified at randomization according to estimated glomerular filtration rate (eGFR): 50 mg/day if eGFR ≥ 50 mL/min/1.73 m
CONCLUSION
In EMPHASIS-HF the eplerenone dose was stratified according to renal function and the treatment effect was not influenced by renal function: 25 mg/day in patients with eGFR 30-49 mL/min/1.73 m
Substances chimiques
Mineralocorticoid Receptor Antagonists
0
Eplerenone
6995V82D0B
Types de publication
Journal Article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
345-351Informations de copyright
© 2019 The Authors. European Journal of Heart Failure © 2019 European Society of Cardiology.